Lumos Diagnostics Receives Authorization for CoviDx ™ SARS-CoV-2 Rapid Antigen Test in Canada


MELBOURNE, Australia, November 03, 2021– (COMMERCIAL THREAD) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted interim order authorization for the test of Lumos CoviDx â„¢ Rapid Antigen SARS-CoV-2. The CoviDx test gives qualified healthcare providers easy-to-interpret, qualitative results within 15 to 20 minutes when COVID-19 is suspected and when performing serial tests on asymptomatic patients.

This press release features multimedia. See the full version here:

Lumos Diagnostics’ CoviDx test provides qualified healthcare providers in Canada with qualitative and easy-to-interpret results within 15 to 20 minutes when COVID-19 is suspected and when performing serial tests on asymptomatic patients. Visit to learn more. (Photo: Business Wire)

“As SARS-CoV-2 continues to evolve, rapid point-of-care testing is a critical part of the Canadian public health response,” said Rob Sambursky, MD, president and CEO of Lumos Diagnostics . “The use of CoviDx as part of routine testing and triage protocols can help advance public health and safety in Canada, while supporting important ongoing efforts to ensure the continuity of commerce, tourism and of education across the country. “

CoviDx is authorized by Health Canada for use by qualified healthcare professionals in the evaluation of symptomatic patients and for serial testing in symptomatic patients. The CoviDx assay is a stand-alone POC assay that uses individual vials of pre-filled Extraction Reagents to facilitate administration in any patient care environment – without any additional instruments or equipment. The test is compatible with nasopharyngeal swab collection and less invasive nasal swab specimen collection and provides a simple “yes / no” result.

With interim prescription authorization from Health Canada, CoviDx is available to qualified healthcare providers across the country through Lumos’ distribution partners.

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and comprehensive point-of-care diagnostic (POC) testing technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers custom test development and manufacturing services for POC testing and proprietary digital reader platforms. Lumos also develops, manufactures and directly markets new Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information on Lumos Diagnostics and the CoviDx SARS-CoV-2 Antigen Rapid Test, visit

Forward-looking statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Lumos and speak only as of the date of this announcement. . Readers are cautioned not to place undue reliance on forward-looking statements.

See the source version on


Media contacts (US and world):
Jennifer Christiansen – Lumos Diagnostics
[email protected]
+1 920 784 3153

Media contact (Australia):
Haley Chartres – H ^ CK
[email protected]
+61 423 139 163

Investor contact:
Matthijs smith
[email protected]
+61 411 137 080
+61 3 9087 1598

Company headquarters:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Road
South Melbourne, VIC 3205
+61 3 9087 1598


Comments are closed.